If the GLP-1 neurons in the hindbrain are activated by physiological or pharmacological methods, or if the central GLP-1 receptors are activated, Rinaman said, this suppresses motivated behaviors such as food intake, drug self-administration, operant responding for drugs, and exploratory behaviors (Maniscalco and Rinaman, 2018)
One of Novo Nordisk's biggest risks, however, is the potential for generics
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
Youll see a board-certified rheumatologist in days, not months, via telehealth across 20+ states with no referral required
Oral certifications were not followed by a signed certification in a timely manner
April 2, 2026: More Vision Loss Lawsuits Filed There are now more than 70 GLP-1 blindness lawsuits grouped together in federal court, with others filed in state court as well
